The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), no specific antiviral drug has been proven effective for the treatment of patients with severe complications. However, a nucleoside prodrug remdesivir (GS-5734) was recently approved by...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X211066646 |
| _version_ | 1798034412218089472 |
|---|---|
| author | Salih Ahmeti Violeta Lokaj-Berisha Besa Gacaferri Lumezi |
| author_facet | Salih Ahmeti Violeta Lokaj-Berisha Besa Gacaferri Lumezi |
| author_sort | Salih Ahmeti |
| collection | DOAJ |
| description | Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), no specific antiviral drug has been proven effective for the treatment of patients with severe complications. However, a nucleoside prodrug remdesivir (GS-5734) was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Preclinical data in animal models of coronavirus diseases have demonstrated that early treatment with remdesivir leads to improved survival and decreased lung injury. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of shorter recovery period and higher odds of improved clinical status in patients with COVID-19. Here, the story of a 79-year-old patient, with 11-year-old left hemiparesis, concomitant cardiovascular disease, infected with SARS-CoV-2, and the clinical improvement after administration of remdesivir during his second hospitalization period is reported. |
| first_indexed | 2024-04-11T20:43:57Z |
| format | Article |
| id | doaj.art-e5be22f9acf04bbda68dbc477c58ed47 |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-04-11T20:43:57Z |
| publishDate | 2022-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-e5be22f9acf04bbda68dbc477c58ed472022-12-22T04:04:06ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2022-01-011010.1177/2050313X211066646The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infectionSalih Ahmeti0Violeta Lokaj-Berisha1Besa Gacaferri Lumezi2University Clinical Center of Kosovo, Prishtina, KosovoDepartment of Physiology and Immunology, Faculty of Medicine, University of Prishtina ‘Hasan Prishtina’, Prishtina, KosovoDepartment of Physiology and Immunology, Faculty of Medicine, University of Prishtina ‘Hasan Prishtina’, Prishtina, KosovoAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), no specific antiviral drug has been proven effective for the treatment of patients with severe complications. However, a nucleoside prodrug remdesivir (GS-5734) was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Preclinical data in animal models of coronavirus diseases have demonstrated that early treatment with remdesivir leads to improved survival and decreased lung injury. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of shorter recovery period and higher odds of improved clinical status in patients with COVID-19. Here, the story of a 79-year-old patient, with 11-year-old left hemiparesis, concomitant cardiovascular disease, infected with SARS-CoV-2, and the clinical improvement after administration of remdesivir during his second hospitalization period is reported.https://doi.org/10.1177/2050313X211066646 |
| spellingShingle | Salih Ahmeti Violeta Lokaj-Berisha Besa Gacaferri Lumezi The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection SAGE Open Medical Case Reports |
| title | The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection |
| title_full | The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection |
| title_fullStr | The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection |
| title_full_unstemmed | The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection |
| title_short | The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection |
| title_sort | clinical course of a 79 year old stroke survivor in the setting of a late onset covid 19 infection |
| url | https://doi.org/10.1177/2050313X211066646 |
| work_keys_str_mv | AT salihahmeti theclinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection AT violetalokajberisha theclinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection AT besagacaferrilumezi theclinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection AT salihahmeti clinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection AT violetalokajberisha clinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection AT besagacaferrilumezi clinicalcourseofa79yearoldstrokesurvivorinthesettingofalateonsetcovid19infection |